The incidence of propofol infusion syndrome in critically-ill patients
Copyright © 2022 Elsevier Inc. All rights reserved..
PURPOSE: PRIS is a potentially fatal syndrome characterized by various clinical symptoms and abnormalities. Experts suggest that propofol treatment duration ≥48 h or dose ≥83 μg/kg/min is associated with developing PRIS. We hypothesized PRIS might be underdiagnosed due to the overlap of PRIS clinical manifestations with critical illnesses.
MATERIALS AND METHODS: Multihospital, retrospective study of adult patients who received continuous propofol infusion ≥48 h or dose ≥60μg/kg/min for >24 h since admission were assessed for the development of PRIS.
RESULTS: The incidence of PRIS was 2.9% with a PRIS-associated mortality rate of 36.8%. In PRIS patients, propofol was administered at a median dose of 36.4 μg/kg/min and over a median duration of 147.0 h. The development of PRIS was observed at a median of 125.0 h post-propofol initiation and a cumulative dose of 276.5 mg/kg. The development of metabolic acidosis (78.9%), cardiac dysfunction (52.6%), hypertriglyceridemia (100%), and rhabdomyolysis (26.3%) were observed in our PRIS patients.
CONCLUSION: PRIS can often be overlooked and underdiagnosed. It is important to monitor for early signs of PRIS in patients who are on prolonged propofol infusion. Prompt recognition and interventions can minimize the dangers resulting from PRIS.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Journal of critical care - 71(2022) vom: 10. Okt., Seite 154098 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Wai Kin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anesthesia |
|---|
| Anmerkungen: |
Date Completed 02.09.2022 Date Revised 14.02.2023 published: Print-Electronic CommentIn: J Crit Care. 2023 Feb;73:154213. - PMID 36403562 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcrc.2022.154098 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342456849 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342456849 | ||
| 003 | DE-627 | ||
| 005 | 20231226014146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcrc.2022.154098 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342456849 | ||
| 035 | |a (NLM)35724444 | ||
| 035 | |a (PII)S0883-9441(22)00127-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Wai Kin |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The incidence of propofol infusion syndrome in critically-ill patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.09.2022 | ||
| 500 | |a Date Revised 14.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Crit Care. 2023 Feb;73:154213. - PMID 36403562 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: PRIS is a potentially fatal syndrome characterized by various clinical symptoms and abnormalities. Experts suggest that propofol treatment duration ≥48 h or dose ≥83 μg/kg/min is associated with developing PRIS. We hypothesized PRIS might be underdiagnosed due to the overlap of PRIS clinical manifestations with critical illnesses | ||
| 520 | |a MATERIALS AND METHODS: Multihospital, retrospective study of adult patients who received continuous propofol infusion ≥48 h or dose ≥60μg/kg/min for >24 h since admission were assessed for the development of PRIS | ||
| 520 | |a RESULTS: The incidence of PRIS was 2.9% with a PRIS-associated mortality rate of 36.8%. In PRIS patients, propofol was administered at a median dose of 36.4 μg/kg/min and over a median duration of 147.0 h. The development of PRIS was observed at a median of 125.0 h post-propofol initiation and a cumulative dose of 276.5 mg/kg. The development of metabolic acidosis (78.9%), cardiac dysfunction (52.6%), hypertriglyceridemia (100%), and rhabdomyolysis (26.3%) were observed in our PRIS patients | ||
| 520 | |a CONCLUSION: PRIS can often be overlooked and underdiagnosed. It is important to monitor for early signs of PRIS in patients who are on prolonged propofol infusion. Prompt recognition and interventions can minimize the dangers resulting from PRIS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anesthesia | |
| 650 | 4 | |a Critical care | |
| 650 | 4 | |a Intensive care unit | |
| 650 | 4 | |a Mechanical ventilation | |
| 650 | 4 | |a Propofol | |
| 650 | 4 | |a Sedation | |
| 650 | 7 | |a Hypnotics and Sedatives |2 NLM | |
| 650 | 7 | |a Propofol |2 NLM | |
| 650 | 7 | |a YI7VU623SF |2 NLM | |
| 700 | 1 | |a Chen, Xian Jie Cindy |e verfasserin |4 aut | |
| 700 | 1 | |a Altshuler, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Islam, Shahidul |e verfasserin |4 aut | |
| 700 | 1 | |a Spiegler, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Emerson, Liane |e verfasserin |4 aut | |
| 700 | 1 | |a Bender, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of critical care |d 1987 |g 71(2022) vom: 10. Okt., Seite 154098 |w (DE-627)NLM074731068 |x 1557-8615 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2022 |g day:10 |g month:10 |g pages:154098 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcrc.2022.154098 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2022 |b 10 |c 10 |h 154098 | ||